Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?

Simple item page
dc.contributor.authorErdoğan A.P.
dc.contributor.authorEkinci F.
dc.contributor.authorKarabaş A.
dc.contributor.authorBalçık O.Y.
dc.contributor.authorBarutça S.
dc.contributor.authorDirican A.
dc.date.accessioned2024-07-22T08:04:40Z
dc.date.available2024-07-22T08:04:40Z
dc.date.issued2022
dc.description.abstractPurpose: To investigate the clinical importance of the inflammatory prognostic index (IPI) in patients with metastatic colorectal cancer treated with regorafenib. Methods: A retrospective analysis of 65 metastatic CRC patients treated with regorafenib between 2015 and 2020 was performed. The association between NLR, PNLR, IPI, and overall survival (OS) and progression-free survival (PFS) was evaluated. Results: According to the cut-off points, patients were divided into two groups. The patients in the high IPI group showed poorer OS compared to patients in the low IPI groups. The PFS was better in patients with low neutrophil-lymphocyte ratio (NLR) and platelet-neutrophil to lymphocyte ratio (PNLR), and the OS was better in patients with low IPI. Conclusion: Among the immune inflammation scores analyzed in mCRC patients receiving regorafenib, NLR and PNLR were the best predictor of recurrence, whereas IPI was the best predictor of long-term survival. After being confirmed by better designed controlled trials, IPI can be used to identify the group of patients who will benefit more from regorafenib treatment. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s12029-021-00642-w
dc.identifier.issn19416628
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12778
dc.language.isoEnglish
dc.publisherSpringer
dc.subjectColorectal Neoplasms
dc.subjectHumans
dc.subjectPhenylurea Compounds
dc.subjectPrognosis
dc.subjectPyridines
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectregorafenib
dc.subjectcarbanilamide derivative
dc.subjectpyridine derivative
dc.subjectregorafenib
dc.subjectArticle
dc.subjectcancer patient
dc.subjectcancer recurrence
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjecthuman
dc.subjectInflammatory Prognostic Index
dc.subjectleukocyte parameters
dc.subjectlong term survival
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastatic colorectal cancer
dc.subjectmulticenter study
dc.subjectneutrophil lymphocyte ratio
dc.subjectoverall survival
dc.subjectplatelet neutrophil to lymphocyte ratio
dc.subjectprediction
dc.subjectprognostic assessment
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjectcolorectal tumor
dc.subjectpathology
dc.subjectprognosis
dc.subjectsurvival rate
dc.titleCould the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu